All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View multiple myeloma content recommended for you
What impact does osseous vs hematogenous extramedullary MM have on patient outcomes?
Featured:
Sergio Rodriguez-RodriguezThe Multiple Myeloma Hub was pleased to speak to Sergio Rodriguez-Rodriguez, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, MX. We asked, What impact does osseous vs hematogenous extramedullary multiple myeloma (EMM) have on patient outcomes?
What impact does osseous vs hematogenous extramedullary MM have on patient outcomes?
In this video interview, Sergio Rodriguez-Rodriguez discusses the outcomes associated with osseous and hematogenous EMM in a cohort of patients treated in Mexico. Rodriguez opens by explaining how osseous and hematogenous EMM manifests in patients and the associated poor prognoses. Rodriguez goes on to highlight the treatment landscape in Mexico, including limited access to novel interventions, as confounding factors influencing these outcomes.
This expert interview is also available in Spanish.
Your opinion matters
Which of the following factors is most important to you when selecting a treatment for patients with multiple myeloma?